Asuntos regulatorios farmacéuticos: acceso abierto

A growing body of preclinical evidence shows that certain cannabinoids, including cannabidiol (CBD) and its derivatives, may play a role in myelinating processes and are promising small particles to be created as a treatment option for the treatment of demyelinating diseases such as multiple sclerosis (MS), stroke, and traumatic brain injury (TBI), which are three of the most widespread demyelinating diseases. Due to the properties described for CBD and its fascinating profile in relation to humans, both the phytocannabinoid and its derivatives could be considered as potential candidates for clinical use. In this study, we will summarize the current advances in the use of CBD and other cannabinoids as potential future medicines. While new research is accelerating the interaction for the era of new drug competitors and drug target screening, the coordinated effort of key participants, for example, key researchers, physicians, and pharmaceutical companies, is expected to bring new treatments to patients.

Many studies have examined beliefs about drug reuse. Although the practice is banned in some pharmacies, it is carried out in other places in life where it relies on visual checks of returned prescriptions as a sign of their quality. One proposal is to integrate sensor technology into prescription packaging as an indicator of its overall quality. Our aim was to measure people's beliefs about prescription reuse, in a study, independently of sensor technology and of the involvement of visual checks by a pharmacist. A between-participants review with two free factors was planned to test the hypothesis that sensors and visual checks would increase support for drug reuse convictions. A survey was used to measure drug reuse convictions and collect subjective feedback. Some participants took part. Attitudes towards medicines presented for reuse, members' apparent predominant burden to accept the prescription, and their expectation to engage in medicine reuse are increased by the presence of sensors on the packages and by the involvement of the medicines specialist in visual control, with the former option generating a more prominent increase than the latter, and the combination of both generating the largest increase. Subjective comments from individuals gave meaning to their interests about medicine reuse, approving the findings.